Biocon Biologics has followed up a US settlement on Stelara (ustekinumab) by striking a further deal with originator Janssen that clears the way for the Indian biosimilars giant to launch its Bmab 1200 version of the top-selling $10bn+ immunology brand in Europe, the UK, Canada and Japan.
Biocon Expands Settlement For Stelara Rival To Cover Global Markets
Indian Biosimilars Giant Had Previously Struck Ustekinumab Deal For US Entry
Biocon Biologics has announced a deal with Janssen that will clear the way for the Indian biosimilars giant to launch its Bmab 1200 ustekinumab rival to Stelara in Europe, the UK, Canada and Japan.
More from Deals
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
• By
The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.
More from Business
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
• By
The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.
• By
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.